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Abstract
Metachromatic leukodystrophy (MLD) is an autosomal recessively inherited sulfatide storage disease caused by deficient activity
of the lysosomal enzyme arylsulfatase A (ASA). Genetic analysis of the ARSA gene is important inMLD diagnosis and screening
of family members. In addition, more information on genotype prevalence will help interpreting MLD population differences
between countries. In this study, we identified 31 different ARSA variants in the patient cohort (n = 67) of the Dutch expertise
center for MLD. The most frequently found variant, c.1283C > T, p.(Pro428Leu), was present in 43 (64%) patients and resulted
in a high prevalence of the juvenile MLD type (58%) in The Netherlands. Furthermore, we observed in five out of six patients
with a non-Caucasian ethnic background previously unreported pathogenic ARSA variants. In total, we report ten novel variants
including four missense, two nonsense, and two frameshift variants and one in-frame indel, which were all predicted to be disease
causing in silico. In addition, one silent variant was found, c.1200C > T, that most likely resulted in erroneous exonic splicing,
including partial skipping of exon 7. The c.1200C > T variant was inherited in cis with the pseudodeficiency allele c.1055A > G,
p.(Asn352Ser) + ∗96A > G. With this study we provide a genetic base of the unique MLD phenotype distribution in
The Netherlands. In addition, our study demonstrated the importance of genetic analysis in MLD diagnosis and the increased
likelihood of unreported, pathogenic ARSA variants in patients with non-Caucasian ethnic backgrounds.
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Introduction
Metachromatic leukodystrophy (MLD, OMIM #250100) is an
autosomal recessively inherited sulfatide storage disease caused
by deficient activity of the lysosomal enzyme arylsulfatase A
(ASA). The disease is characterized by progressive central and
peripheral demyelination, resulting in severe neurological deteri-
oration. The most prominent signs and symptoms are ataxia,
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spasticity, cognitive decline, behavioral disturbances, peripheral
neuropathy, and eventually a severely disabled state with epilep-
sy, painful spasticity, loss of motor and communication skills,
and premature death [1]. Based on the age of symptom onset,
three main MLD phenotypes can be distinguished: late-infantile
(< 30 months), juvenile (2.5–16 years), and adult (> 16 years)
MLD, with often an extra distinction between early-juvenile
(2.5–6 years) and late-juvenile (6–16 years) MLD patients. A
severe phenotype with symptom onset at a younger age, faster
disease progression and shorter life expectancy, is usually ac-
companied by lower levels of residual ASA activity. However,
a close correlation between disease severity and residual ASA
activity could not be established [2–4].
Residual ASA activity levels are (partially) dependent on
the two functional types of pathogenicARSA variants that could
be present: those resulting in inactive ASA (0-alleles, r.0), in-
cluding the common splice donor site variants c.465 + 1G > A
(r.0) and c.1210 + 1G > A (r.0), and those resulting in some
residual ASA activity (R-alleles), including the frequently
found missense variants c.1283C > T, p.(Pro428Leu) and
c.542T > G, p.(Ile181Ser) [5]. Carriers of one pathogenic
ARSA variant typically have reduced ASA activity although
far above the ASA activity range of MLD patients [4, 6].
Although determination of ASA activity is very useful, in com-
bination with the clinical symptoms and genetic findings, to
diagnose MLD, it is not able to distinguish the different MLD
phenotypes. ASA activity levels (1) show considerable vari-
ability between patients with the same clinical phenotype, even
within families [7, 8]; (2) can vary within individual patients at
repeated testing due to inter-assay variability [7]; and (3) can be
reduced within the range of MLD patients in healthy individ-
uals carrying two copies of the pseudodeficiency (Pd) allele
c.1055A > G, p.(Asn352Ser) + ∗96A > G [9]. Due to the high
frequency of the Pd allele, MLD patients may also have one or
two copies of this allele in addition to their pathogenic ARSA
variants. Some ARSA variants have been found to inherit in cis
with the Pd allele [6]. Therefore, accurate genetic anal-
ysis of the ARSA gene is necessary in MLD diagnosis,
especially when screening of (pre-symptomatic) family
members is indicated [4].
In this study, we report the prevalence of pathogenic ARSA
variants and MLD phenotypes in the patient cohort of the




In this retrospective study, approved by the institutional re-
view board and with appropriate consent of patients/their
guardians, we included 76 patients who were referred to the
Amsterdam University Medical Center (Amsterdam UMC)
with a confirmed diagnosis of MLD. We considered MLD
to be confirmed when at least two different tests were com-
patible with the diagnosis: homozygosity or compound het-
erozygosity for two pathogenic ARSA variants, increased uri-
nary sulfatide excretion and/or decreased ASA activity within
the range of MLD patients analyzed according to the Baum
assay ormodified Baum assay either at 0 or 4 °C depending on
the laboratory [10–12], or when genetic testing of an affected
sibling identified the same pathogenic ARSA variants as the
index patient. In all but two patients, ARSAwas tested directly
by Sanger sequencing. In these two patients, ARSA mutations
were detected using next-generation sequencing techniques
(whole exome sequencing (WES) in a patient with unex-
plained polyneuropathy (MLD-67) and WES-based testing
of a leukodystrophy gene panel in a patient with unexplained
brain white matter abnormalities (MLD-81)). For most pa-
tients, both parents were tested to confirm the presence of
mutations on two different alleles.
Genetic and biochemical tests were performed in themetabol-
ic laboratory of the Amsterdam UMC, in laboratories collaborat-
ing with the referring hospitals including the metabolic laborato-
ries of the Erasmus University Medical Center (Rotterdam),
Radboud University Medical Center (Nijmegen), and
University Medical Center Groningen (Groningen), or at both
locations. Results of genetic analysis of the ARSA gene, ASA
activity, urinary sulfatide excretion, and data on ethnicity, sex,
age of symptom onset, presenting symptoms, presence of affect-
ed siblings, and consanguinity of the parents were collected from
patient records. Patients who had not undergone genetic testing
were excluded from this study.
According to the age of symptom onset, patients were
grouped into a late-infantile, early-juvenile, late-juvenile,
and adult phenotype. Reference-corrected residual ASA activ-
ity levels were constructed by expressing the ASA activity
level of each individual patient as a percentage of the mean
and the lowest boundary of the used reference values and in
number of standard deviations (s.d.) from the mean when
available. These reference-corrected residual ASA activity
levels were used to examine the correlation between MLD
phenotype and mean residual ASA activity with the
Spearman rank correlation test and the independent sample t
test in RStudio (version 3.6.1).
ARSA variants
We reported all identified ARSA variants according to the
current nomenclature guidelines (http://www.varnomen.
hgvs.org) [13] and GenBank accession number NM_
000487.5 (https://www.ncbi.nlm.nih.gov/nuccore/NM_
000487.5) [14]. We consulted different databases, including
1000 Genome, Clinvar, and the Human Gene Mutation
Database (HGMD), to investigate whether variants had
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previously been reported. For novel variants, we indicated
whether they were missense, nonsense, silent or splice-site
variants, or in-frame, frameshift deletions, insertions, duplica-
tions or indels. Furthermore, when available, data on parental
presence of variants were analyzed to establish whether vari-
ants occurred de novo, whether they were biallelic or
monoallelic, and whether they inherited in trans or cis with
the Pd allele (when present). Potential pathogenicity of the
variants was predicted in silico using MutationTaster, SIFT
(Sorting Intolerant From Tolerant), PROVEAN (Protein
Variant Effect Analyzer), and PolyPhen-2. For all variants,
we investigated whether the affected amino acid was involved
in the catalytic site or dimer interface of ASA based on the
location within the crystal structures of human ASAmonomer
and octamer (PDB-ID: 1AUK) using PyMol [15, 16]. Fig. 1
was prepared with RStudio (version 3.6.1), using the packages
“ggplot2” and “packcircles” [17]. Fig. 2 was made with
PyMol based on the crystal structures of human ASA mono-
mer and octamer (PDB-ID: 1AUK) [15, 16].
For one variant, c.1200C > T, p.(=), the effect on exonic
splicing of ARSA pre-mRNA was analyzed by reverse
transcriptase-polymerase chain reaction (RT-PCR) using the
primers 5′-GTATCGGAAAGAGCCTGCTG-3′ and 5′-
ACGTTATCAGGCACAAACCC-3′ and the PCR conditions
as specified by the manufacturer. For this purpose, peripheral
blood was collected in PAXgene collection tubes, and mRNA
was extracted using a PAXgene Blood RNA Kit (#762164,
PreAnalytiX, Qiagen/BD) according to the manufacturer’s in-
structions. Fig. 3, demonstrating the sequence of the mutated
ARSA cDNA fragment of the patient compared to the ARSA
cDNA sequence of a control, was made with SnapGene 4.2.9.
Results
Patient characteristics
Results of genetic analysis of the ARSA gene were avail-
able for 67 of the 76 MLD patients. The other nine patients
had not undergone genetic testing and were therefore ex-
cluded from the study. Sixty-one of the 67 included pa-
tients had a Western European (Caucasian) ethnic back-
ground and six had a non-Caucasian ethnic background.
The age of symptom onset ranged from 12 months to
36 years. Eleven patients (16%) had the late-infantile onset
type of whom five had a non-Caucasian ethnic background,
39 patients (58%) had the juvenile onset type of whom
fourteen patients with the early-juvenile (36%) and 25 pa-
tients with the late-juvenile (64%) phenotype, and seven-
teen patients (25%) had the adult onset type of MLD. An
overview of individual patient characteristics is presented in
Supplementary Table 1. Patients with later onset forms did
not necessarily have higher residual ASA activity levels.
Mean ASA activity per MLD phenotype, calculated as per-
centage of the mean and lowest boundary of the used ref-
erence values and in number of s.d. from the mean, are
given in Supplementary Table 2. These reference-
corrected means of residual ASA activity had also no or
only a (very) weak correlation with the MLD phenotype
(Spearman rank correlation coefficients of 0.11 (p = 0.41),
0.26 (p = 0.05), and 0.13 (p = 0.36), respectively), also
when analyzed in homozygous MLD patients only
(Spearman rank correlation coefficients of − 0.08 (p =
0.79), 0.10 (p = 0.71), and 0.00 (p = 1.00), respectively).
Prevalence of ARSA variants
We identified a total of 31 different ARSA variants. The
most frequent variant was c.1283C > T, p.(Pro428Leu),
accounting for 44% of all pathogenic ARSA variants.
Heterozygosity for this variant was observed in 26 patients
(thirteen early-juvenile, nine late-juvenile, and four adult
MLD patients), and homozygosity for the c.1283C > T
variant was observed in seventeen patients (nine late-
juvenile and eight adult MLD patients). In patients carry-
ing the c.1283C > T variant, a strong correlation between
MLD phenotype and reference-corrected means of residual
ASA activity could again not be established (Spearman
rank correlation coefficients of − 0.06 (p = 0.72; “mean
corrected”), 0.06 (p = 0.74; “lowest boundary corrected”),
and − 0.13 (p = 0.48; “s.d. corrected”)). Of all patients ho-
mozygous for the c.1283C > T variant, juvenile MLD pa-
tients showed even higher reference-corrected means of
residual ASA activity compared to adult MLD patients
(“mean corrected”: 11.4 vs 6.2, p = 0.003; “lowest bound-
ary corrected”: 20.7 vs 14.9, p = 0.018; “s.d. corrected”: −
2.7 vs − 3.0, p = 0.314). All patients with the c.1283C > T
variant had a Western European (Caucasian) ethnic back-
ground, and none of the patients homozygous for c.1283C
> T became symptomatic before the age of 6 years.
Importantly, none of the late-infantile MLD patients car-
ried the c.1283C > T variant. The prevalence of each one of
the other 30 pathogenic ARSA variants in our cohort ranged
between 1 and 8%. The comparative prevalence of all
ARSA variants in our cohort with their distribution of
MLD type, zygosity, and ethnicity is shown in Fig. 1. In
two siblings with MLD, only one pathogenic ARSA variant
was detected. Finally, the Pd allele c.1055A > G,
p.(Asn352Ser) + ∗96A > G was identified in 10 (15%)
MLD patients. Heterozygosity for this variant was ob-
served in eight Caucasian patients (one late-infantile, two
early-juvenile, two late-juvenile, and three adult MLD pa-
tients), while homozygosity for this variant was observed
in two non-Caucasian patients (one late-infantile and one
late-juvenile MLD patient).
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Fig. 1 Comparative prevalence of all pathogenic ARSA variants in the
patient cohort (GenBank accession number NM_000487.5) with their
distribution of MLD type, zygosity, and ethnicity. a The size of the
circle indicates the prevalence of the variant, and the color category of
the circle corresponds the gene location shown in Fig. 2c. The most
prevalent variant was c.1283C > T, p.(Pro428Leu), accounting for 45%
of all the pathogenic ARSA variants, present in 43 out of 67 patients
(64%). All patients carrying this variant had the early-juvenile (all
heterozygous, n = 13), late-juvenile (heterozygous n = 9, homozygous
n = 9), or adult MLD type (heterozygous n = 4, homozygous n = 8). The
second and third most prevalent variant were c.465 + 1G > A (r.0) and
c.293C > T, p.(Ser98Phe), accounting for respectively 8% and 6% of all
pathogenic ARSA variants. b Table showing the number of patients and
the distribution of MLD type, zygosity, and patient ethnicity for each of
the pathogenic ARSA variants
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Identification of ten novel variants
Five out of the six patients with a non-Caucasian ethnic back-
ground, two of whom were siblings, had a previously unre-
ported pathogenic ARSA variant. In total, we identified ten
novel pathogenic ARSA variants in thirteen patients from elev-
en unrelated families. An overview of clinical and genetic
characteristics of these patients is presented in Table 1.
Almost half (6/13) of these patients suffered from the late-
infantile MLD form. Two late-infantile patients, both from
consanguineous families, were homozygous for the novel var-
iants (c.1123_1126del, p.(Leu375Serfs*47) or c.905G > A,
p.(Cys302Tyr)). Except for these patients and one late-
juvenile patient being homozygous for the novel variant
c.1200C > T, p.(=), all other patients were compound hetero-
zygous with a second, previously reported ARSA variant.
Based on parental genetic data, we were able to establish that
none of the variants occurred de novo and that the c.1200C >
T variant was inherited in cis with the Pd allele c.1055A > G,
p.(Asn352Ser) + ∗96A > G. The distribution of the novel var-
iants over the ARSA gene and their location within the ASA
protein are shown in Fig. 2.
Characterization of novel variants
The ten novel variants included four missense variants, two
nonsense variants, two frameshift variants (one single-base pair
duplication and one four-base pair deletion), one in-frame indel,
and one silent variant. None of these variants were present in
1000 Genome database, Clinvar, and HGMD. All novel vari-
ants were predicted to be disease causing by MutationTaster.
All missense variants were predicted to be deleterious and prob-
ably damaging by SIFT, PROVEAN, and Polyphen-2. The in-
frame indel variant (c.836_837delTCinsAA) was predicted to
be possible damaging with HumDiv and HumVar scores of
0.78 and 0.87, respectively. The affected amino acids glycine
on position 124 (c.371G >A), cysteine on position 302 (c.905G
> A), and leucine on position 336 (c.1007 T > C) were highly
con s e r v ed , wh i l e i s o l e u c i n e on po s i t i o n 279
(c.836_837delTCinsAA) and leucine on position 360
(c.1079T > C) were moderately conserved. The silent
c.1200C > T variant most likely created a cryptic splice-
acceptor site in exon 7 (SpliceSiteFinder-like increase in the
AG acceptor site at c.1208_1209 from 87.5 to 90.8), resulting
in erroneous exonic splicing. RT-PCR analysis on ARSA
mRNA extracted from the patient’s blood showed indeed mul-
tiple splicing errors including partial skipping of exon 7 (Fig. 3).
The sixth patient with a non-Caucasian ethnic background
(MLD-34) had a North African ethnicity. Presenting signs
were absence seizures, ataxia, and spasticity from age
12 months, and ASA activity was 7.0 nmol/h/mg (ref: –
90 nmol/h/mg). She was homozygous for the c.545C > G,
p.(Pro182Arg) variant and the Pd allele and had
consanguineous parents. This variant was previously reported
in one early-juvenile MLD patient heterozygous for this var-
iant (second allele c.1283C > T) without data on ethnic back-
ground or the presence of the Pd allele [18].
Discussion
The late-infantile MLD type is the most prevalent worldwide
(48% of all patients) among MLD patients [3]. In contrast, we
observed that in The Netherlands the juvenile type is much
more common (58% of all patients). We showed that this is
due to the high frequency of the c.1283C > T, p.(Pro428Leu)
missense variant in Dutch MLD patients, a pathogenic ARSA
variant that affects the stability of the ASA octamer by lower-
ing the acidic pH [19]. The fact that this variant was not found
in any late-infantile MLD patient and was found only in a
heterozygous state in early-juvenile MLD patients confirms
that this variant is associated with a later disease onset [3, 5,
20], however without strict correlation with relatively high
residual ASA activity levels. The common observation that
patients with later onset forms do not necessarily have higher
residual ASA activity levels might be caused by multiple fac-
tors; e.g., ARSA variants might influence other ASA properties
in addition to its activity in blood leukocytes. It is however
important to consider that the ASA activity levels in this study
were measured in different laboratories. Other possible expla-
nations are therefore assay performance differences between
laboratories or inter-assay variability.
In addition, we identified ten novel pathogenicARSA variants.
Twomissense variants affected the same amino acid as missense
variants previously reported as pathogenic. These two missense
variants are the c.905G > A p.(Cys302Tyr) variant correspond-
ing to the c.905G > T, p.(Cys302Phe) [21], and the c.371G > A,
p.(Gly124Asp) variant corresponding to the c.370G > A,
p.(Gly124Ser) and c.370G > T, p.(Gly124Cys) variants [22,
23]. Moreover, we identified the c.1200C > T variant as a poten-
tial disease-causing silent variant. Silent variants are often con-
sidered to be non–disease-causing since the amino acid sequence
and subsequently protein structure and function are thought not
to be altered [24]. However, the c.1200C > T variant seems to
result inmultiple splicing errors, and therefore, in agreement with
segregation data in this family, to be a pathogenic ARSA variant.
However, at this stage we cannot exclude the possibility that the
observed altered pre-mRNA splicing of ARSA is due to an un-
known intronic variant, in cis with the c.1200C > T variant.
Taking into account the residual ASA activity and late-juvenile
phenotype, it is likely that low levels of mRNA are spliced prop-
erly. Nevertheless, this is speculation and has not yet been inves-
tigated by analyzing multiple cDNA clones.
Remarkably, the presented group of patients with a novel
ARSA variant had a much higher proportion of MLD patients
with the late-infantile type (46%) and a non-Caucasian ethnicity
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Fig. 2 Pathogenic missense ARSA variants identified in this study. a
3D model of the ASA monomer showing novel pathogenic ARSA
missense variants. Helices, β-sheets, and loops are shown as ribbons,
arrows, and threads, respectively. The amino acid residues affected
by the novel pathogenic ARSA missense variants (in bold) and
c.1283C > T variant (in italic) are indicated with black spheres and
highlighted in colors corresponding to their gene locations shown in
Fig. 2c. The amino acid residues forming the catalytic site of ASA
are highlighted in yellow. b 3D model of three subunits of the ASA
octamer showing the location of all pathogenic missense ARSA
variants identified in this study. Helices, β-sheets and loops are
shown as ribbons, arrows and threads, respectively. Affected amino
acid residues in the catalytic site or dimer interface are indicated with
black spheres and highlighted in colors. The amino acid residues
affected by previously reported variants are highlighted in green
and those affected by the novel variants are highlighted in cyan.
The common c.1283C > T variant is highlighted in blue. (c) The
distribution of the novel pathogenic variants (in bold) throughout the
ARSA gene. For the record, also the previously reported variants
heterozygous with these novel variants are shown in italic.
Numbered boxes represent the positions of the eight exons of the
ARSA gene containing 509 amino acids (GenBank accession number
NM_000487.5)
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(38%) compared to our full patient cohort (respectively 16% and
9%). This might be caused by the natural population prevalence
of ARSA variants but might also be influenced by
underdiagnosing and underreporting MLD patients with other
ethnic backgrounds [25, 26]. This is a point of concern, consid-
ering global migration and in case genetic tests are employed that
only test for common ARSA variants. False-negative MLD diag-
nosis could result in withholding treatment opportunities for oth-
erwise eligible patients, especially since experimental therapies
including gene therapy and intrathecal enzyme-replacement ther-
apy are evolving. More phenotype information on pathogenic
ARSA variants will also help interpreting results from the pilot
Fig. 3 Demonstration of multiple splicing errors including partial
skipping of exon 7 due to the c.1200C > T variant. ARSA mRNA was
amplified by RT-PCR. The upper panel shows the cDNA sequence of a
control, and the lower panel shows the sequence of the mutated cDNA
fragment of the patient. The red bars indicate part of patient cDNA
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































newborn screening programs starting in parts of the USA and
Europe, as prediction of the most likely MLD form will influ-
ence treatment decisions. Fortunately, novel ARSA variants in
previously less frequently studied ethnicities are increasingly
repor ted . A few examples are the c .847G > A,
p.(Asp283Asn), c.853G > A, p.(Asp285Asn), and c.1031C
> A, p.(Ala344Asp) variants in Sri Lanka [27]; the c.256C >
G, p.(Arg86Gly), c.344 T > C, p.(Leu115Pro), and c.693C >
A, p.(His231Gln) variants in respectively Jordan, Pakistan,
and Tunisia [28–30]; and the c.1070G > T, p.(Gly357Val),
c.585G > T, p.(Trp195Cys), c.849C > G, p.(Asp283Glu),
and c.911A > G, p.(Lys304Arg) variants in Iran [31, 32].
Finally, Narayanan et al. recently reported 36 ARSA variants
in MLD patients from India, and no less than sixteen of them
were novel [33].
To conclude, with this study we provide a genetic base of the
unique MLD phenotype distribution in The Netherlands. Our
study also demonstrates the importance of genetic analyses in
diagnosing and phenotypingMLD patients and stresses the need
for sequencing the entire ARSA gene in patients with suspected
MLD, instead of screening only for common ARSA variants. In
case of variants of unknown significance and to confirm patho-
genic variants, ASA activity in leukocytes or fibroblasts should
bemeasured. Clinicians should be aware of unknown pathogenic
ARSA variants in patients with various ethnic backgrounds.
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